Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.

被引：0
|
作者：
Jin, Min [1 ]
Yang, Shengli [1 ]
Liu, Junli [1 ]
Zhang, Jieying [1 ]
Zhao, Lei [1 ]
Yu, Dandan [1 ]
Lin, Zhenyu [1 ]
Li, Pindong [1 ]
Wang, Jing [1 ]
Xue, Jun [1 ]
Ma, Hong [1 ]
Hu, Jianli [1 ]
Zhang, Tao [1 ]
Liu, Hongli [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
3282-3306-3348-4026; 261-492-3532-2370-7650-2700; 130-540-543-12277-2683; 613-135-244-3829; 261-492-3532-2370-5109; 613-225-3248-9559-9794-11285; 4; 3; 2; 2461; 2444; 1704; 5; 38116-38094-8;
D O I：
10.1200/JCO.2024.42.3_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [1] A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 407 - 407
  • [2] Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.
    Ma, Fei
    Luo, Suxia
    Zhang, Bin
    Ma, Qi
    Ji, Sheqing
    Zhang, Zhandong
    Zhang, Yonglei
    Yang, Wei
    Peng, Liangqun
    Guo, Dandan
    Ren, Jinjun
    Zhang, Yuan
    Su, Yueyue
    Li, Jing
    Liu, Wentao
    Huang, Jinxi
    Yuan, Weiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
    Le Zhang
    Weixue Wang
    Shaohua Ge
    Hongli Li
    Ming Bai
    Jingjing Duan
    Yuchong Yang
    Tao Ning
    Rui Liu
    Xia Wang
    Zhi Ji
    Feixue Wang
    Haiyang Zhang
    Yi Ba
    Ting Deng
    BMC Cancer, 23
  • [4] Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial.
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Lu, Yun-Xin
    Bai, Bing
    Zhang, Yang
    Wang, Zhi-Qiang
    Liu, Yu
    Chen, Jian-Wen
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 358 - 358
  • [5] Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
    Zhang, Le
    Wang, Weixue
    Ge, Shaohua
    Li, Hongli
    Bai, Ming
    Duan, Jingjing
    Yang, Yuchong
    Ning, Tao
    Liu, Rui
    Wang, Xia
    Ji, Zhi
    Wang, Feixue
    Zhang, Haiyang
    Ba, Yi
    Deng, Ting
    BMC CANCER, 2023, 23 (01)
  • [6] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Chao Jing
    Junyun Wang
    Mingyue Zhu
    Zhigang Bai
    Baoyi Zhao
    Jun Zhang
    Jie Yin
    Xiaobao Yang
    Zongzhi Liu
    Zhongtao Zhang
    Wei Deng
    Cancer Immunology, Immunotherapy, 2022, 71 : 2597 - 2608
  • [7] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Jing, Chao
    Wang, Junyun
    Zhu, Mingyue
    Bai, Zhigang
    Zhao, Baoyi
    Zhang, Jun
    Yin, Jie
    Yang, Xiaobao
    Liu, Zongzhi
    Zhang, Zhongtao
    Deng, Wei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2597 - 2608
  • [8] Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial
    Ding, Xuewei
    Li, Bin
    Xue, Qiang
    Cai, Mingzhi
    Cui, Jingli
    Wang, Baogui
    Ke, Bin
    Zhang, Rupeng
    Liang, Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [10] A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Meng, Xiangrui
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 335 - 335
12345